Gsk (GSK) Total Liabilities (2009 - 2026)

Gsk (GSK) has 18 years of Total Liabilities data on file, last reported at -$59.8 billion in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities changed 0.2% year-over-year to -$59.8 billion; the trailing twelve-month figure through Jun 2026 stood at -$59.8 billion (changed 0.2% YoY), and the FY2025 full-year result was -$60.1 billion, down 1.33% from the prior year.
• Total Liabilities was -$59.8 billion for Q2 2026 at Gsk, up from -$61.3 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of -$24.4 billion in Q1 2022 to a low of -$83.6 billion in Q2 2022.
• A 5-year average of -$58.6 billion and a median of -$59.4 billion in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 69.01% in 2022 and tumbled 135.68% in 2023, its largest moves.
• Gsk's Total Liabilities stood at -$58.7 billion in 2022, then gained by 2.3% to -$57.4 billion in 2023, then fell by 3.79% to -$59.5 billion in 2024, then retreated by 0.92% to -$60.1 billion in 2025, then increased by 0.48% to -$59.8 billion in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were -$59.8 billion in Q2 2026, -$61.3 billion in Q1 2026, and -$60.1 billion in Q4 2025.